ClinicalTrials.gg
CompletedNCT03601637Updated Jan 6, 2023Results posted

Safety and Pharmacokinetic Study of Lumacaftor/Ivacaftor in Participants 1 to Less Than 2 Years of Age With Cystic Fibrosis, Homozygous for F508del

A Phase 3 interventional study of LUM and IVA in Cystic Fibrosis, sponsored by Vertex Pharmaceuticals Incorporated. Completed at 27 sites in 2 countries. Open to participants aged 12 Months to 23 Months. Per ClinicalTrials.gov, last updated 2023-01-06.

Sponsored by Vertex Pharmaceuticals Incorporated · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Non-randomized
Ages
12 Months to 23 Months
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing lumacaftor in Cystic Fibrosis — none open to participants now, none under way, none of them phase 3. lumacaftor · Cystic Fibrosis.

Enrollment
12th of 20
61 · median 66
Started
2018
with 1 other
Phase 3
10 of 20
none open now
Registered
18th of 20
by date
Lead sponsor
20 of 20
Vertex Pharmaceuticals Incorporated

Among the 20 studies testing lumacaftor in Cystic Fibrosis, this one is the 12th largest by enrollment, is one of 2 that started in 2018, is one of 10 in phase 3, and was the 18th registered.

Cystic Fibrosis

1,621 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

None of the 20 studies testing lumacaftor in Cystic Fibrosis is open now. The open studies under Cystic Fibrosis, anywhere →

About lumacaftor

lumacaftor: first FDA approval 2015 (ORKAMBI), first EMA approval 2015. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 86 take children under 18; 41 take healthy volunteers.

This study: 12 Months to 23 Months · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 20 studies testing lumacaftor in Cystic Fibrosis as a file.
02

Study summary

This study will evaluate the safety and pharmacokinetics (PK) of lumacaftor (LUM) and ivacaftor (IVA) in participants 1 to less than 2 years of age with cystic fibrosis (CF), homozygous for F508del (F/F).

03

Conditions studied

  • Cystic Fibrosis

Browse trials for

04

Who can participate

Ages eligible
12 Months to 23 Months
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • Participants will be 1 to less than 2 years of age on day 1 of the relevant part of the study
  • Homozygous for F508del (F/F)

Key Exclusion Criteria:

  • Any laboratory abnormalities at the screening visit that would interfere with the study assessments or pose an undue risk for the participants
  • Solid organ or hematological transplantation

Other protocol defined Inclusion/Exclusion criteria may apply.

Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
61 participants (actual)

Study arms

  • Experimental
    Part A: LUM/IVA

    Participants weighing 7 to less than (\<)10 kilograms (kg) at screening received LUM 75 milligrams (mg)/IVA 94 mg fixed-dose combination (FDC) every 12 hours (q12h) and those weighing 10 to \<14 kg at screening received LUM 100 mg/IVA 125 mg q12h for 15 days. Participants weighing greater than or equal to (\>=)14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 15 days.

    Drug: LUM · Drug: IVA

  • Experimental
    Part B: LUM/IVA

    Participants weighing 7 to \<9 kg at screening received LUM 75 mg/IVA 94 mg FDC q12h and those weighing 9 to \<14 kg received LUM 100 mg/IVA 125 mg q12h for 24 weeks. Participants weighing \>=14 kg at screening received LUM 150 mg/IVA 188 mg FDC q12h for 24 weeks. Doses were adjusted upwards for changes in weight.

    Drug: LUM · Drug: IVA

Interventions

  • DrugLUM

    Fixed Dose Combination (FDC) granules (LUM/IVA).

    Also known as: lumacaftor, VX-809

  • DrugIVA

    FDC granules (LUM/IVA).

    Also known as: ivacaftor, VX-770

06

What researchers measure

Primary outcomes

  1. Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA

    Time frame: Day 1 and Day 15

  2. Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA

    Time frame: Pre-dose at Day 8 and Day 15

  3. Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Week 26

Secondary outcomes

  1. Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: From Day 1 up to Day 25

  2. Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)

    Time frame: Pre-dose at Day 8 and Day 15

  3. Part B: Absolute Change in Sweat Chloride

    Time frame: From Baseline at Week 24

  4. Part B: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)

    Time frame: Pre-dose at Day 15, Week 4, Week 12 and Week 24

07

Results

Posted Jan 6, 2023

Participant flow

Participant flow — Overall Study
MilestonePart A: LUM/IVAPart B: LUM/IVA
Started1446
Completed1343
Not completed13
Withdrew: Withdrawal of consent (not due to adverse event)01
Withdrew: Adverse event11
Withdrew: Other01

Outcome measures

PrimaryPart A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA
Time frame:
Day 1 and Day 15
Reported as:
Mean · nanograms per milliliter (ng/mL)
Part A: Observed Plasma Concentrations From 3-4 Hours (C3-4hr) of LUM and IVA
nanograms per milliliter (ng/mL)Part A: LUM 75 mg/IVA 94 mgPart A: LUM 100 mg/IVA 125 mg
Day 1: LUM14600 ± 556012600 ± 7190
Day 15: LUM16600 ± 959013900 ± 5800
Day 1: IVA1620 ± 6481320 ± 804
Day 15: IVA718 ± 352496 ± 268
PrimaryPart A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA
Time frame:
Pre-dose at Day 8 and Day 15
Reported as:
Mean · ng/mL
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA
ng/mLPart A: LUM 75 mg/IVA 94 mgPart A: LUM 100 mg/IVA 125 mg
Day 8: LUM12000 ± 888012800 ± 3900
Day 15: LUM8380 ± 779010500 ± 3070
Day 8: IVA169 ± 75.5185 ± 101
Day 15: IVA78.9 ± 19.1120 ± 60.5
PrimaryPart B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Day 1 up to Week 26
Reported as:
Number · participants
Part B : Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart B: LUM/IVA
Participants with TEAEs44
Participants with SAEs5
SecondaryPart A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Time frame:
From Day 1 up to Day 25
Reported as:
Number · participants
Part A: Safety and Tolerability as Assessed by Number of Participants With Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
participantsPart A: LUM/IVA
Participants with TEAEs12
Participants with SAEs0
SecondaryPart A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)
Time frame:
Pre-dose at Day 8 and Day 15
Reported as:
Mean · ng/mL
Part A: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)
ng/mLPart A: LUM 75 mg/IVA 94 mgPart A: LUM 100 mg/IVA 125 mg
Day 8: M28-LUM1410 ± 7911470 ± 365
Day 15: M28-LUM1460 ± 10601370 ± 468
Day 8: M1-IVA606 ± 298842 ± 527
Day 15: M1-IVA284 ± 70.2604 ± 394
Day 8: M6-IVA2380 ± 8433290 ± 1830
Day 15: M6-IVA1460 ± 7632800 ± 2300
SecondaryPart B: Absolute Change in Sweat Chloride
Time frame:
From Baseline at Week 24
Reported as:
Mean · Millimole per liter (mmol/L)
Part B: Absolute Change in Sweat Chloride
Millimole per liter (mmol/L)Part B: LUM/IVA
Part B: Absolute Change in Sweat Chloride-29.1 ± 13.5
SecondaryPart B: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)
Time frame:
Pre-dose at Day 15, Week 4, Week 12 and Week 24
Reported as:
Mean · ng/mL
Part B: Observed Pre-dose Plasma Concentration (Ctrough) of LUM and IVA and Their Respective Metabolites (M28-LUM, M1-IVA and M6-IVA)
ng/mLPart B: LUM 75 mg/IVA 94 mgPart B: LUM 100 mg/IVA 125 mgPart B: LUM 150 mg/IVA 188 mg
Day 15: LUM135009030 ± 4390887
Week 4: LUM219009370 ± 50301000
Week 12: LUM121009160 ± 4400566
Week 24: LUM112008930 ± 5310288
Day 15: M28-LUM14601260 ± 528786
Week 4: M28-LUM15701340 ± 579602
Week 12: M28-LUM17401440 ± 599501
Week 24: M28-LUM18701470 ± 548569
Day 15: IVA213112 ± 68.33.68
Week 4: IVA267112 ± 82.911.4
Week 12: IVA28691.7 ± 44.72.18
Week 24: IVA37.1144 ± 2962.86
Day 15: M1-IVA1420437 ± 29118.1
Week 4: M1-IVA1930466 ± 35958.0
Week 12: M1-IVA759418 ± 23618.3
Week 24: M1-IVA256499 ± 61318.5
Day 15: M6-IVA47401930 ± 146043.9
Week 4: M6-IVA90901970 ± 1490131
Week 12: M6-IVA35201950 ± 143046.5
Week 24: M6-IVA13201740 ± 113063.3

Adverse events

Collected over From Day 1 Through Safety Follow-up Period (up to Day 25 for Part A and up to Week 26 for Part B). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Part A: LUM/IVA0/14 (0%)0/14 (0%)12/14 (85.7%)
Part B: LUM/IVA0/46 (0%)5/46 (10.9%)42/46 (91.3%)
Most frequent serious events
Most frequent serious events
EventPart A: LUM/IVAPart B: LUM/IVA
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/143/46
Post procedural feverInjury, poisoning and procedural complications0/141/46
Distal intestinal obstruction syndromeGastrointestinal disorders0/141/46
Most frequent other events
Showing 10 of 22
Most frequent other events
EventPart A: LUM/IVAPart B: LUM/IVA
RhinorrhoeaRespiratory, thoracic and mediastinal disorders5/145/46
CoughRespiratory, thoracic and mediastinal disorders4/1416/46
PyrexiaGeneral disorders1/1410/46
RashSkin and subcutaneous tissue disorders3/144/46
VomitingGastrointestinal disorders0/148/46
Infective pulmonary exacerbation of cystic fibrosisInfections and infestations0/148/46
InfluenzaInfections and infestations2/140/46
Upper respiratory tract infectionInfections and infestations1/146/46
Pseudomonas test positiveInvestigations0/145/46
ConstipationGastrointestinal disorders1/145/46

Baseline characteristics

All participants who received at least one dose of the study drug during the treatment period were included in the baseline analysis. The baseline analysis was collected for the overall treatment arm, irrespective of a weight-based dose regimen. Therefore, the analysis is reported in a single arm for each study part (Part A: LUM/IVA and Part B: LUM/IVA).

Age, Categorical
Age, Categorical(Participants)Part A: LUM/IVAPart B: LUM/IVATotal
<=18 years144660
Between 18 and 65 years000
>=65 years000
Sex: Female, Male
Sex: Female, Male(Participants)Part A: LUM/IVAPart B: LUM/IVATotal
Female72431
Male72229
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Part A: LUM/IVAPart B: LUM/IVATotal
Hispanic or Latino123
Not Hispanic or Latino133750
Unknown or Not Reported077
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Part A: LUM/IVAPart B: LUM/IVATotal
White143448
Black or African American011
Asian000
American Indian or Alaska Native011
Native Hawaiian or Other Pacific Islander000
Not collected per local regulations077
Other033
08

Study locations

27 sites
  • University of Alabama at Birmingham
    Birmingham, Alabama 35233, United States
  • Arkansas Children's Hospital
    Little Rock, Arkansas 72202, United States
  • Stanford University
    Palo Alto, California 94304, United States
  • Children's Hospital Colorado
    Aurora, Colorado 80045, United States
  • Yale New Haven Medical Center
    New Haven, Connecticut 06511, United States
  • Nemours / Alfred I. duPont Hospital for Children
    Wilmington, Delaware 19803, United States
  • Children's Healthcare of Atlanta
    Atlanta, Georgia 30329, United States
  • Ann & Robert Lurie Children's Hospital of Chicago
    Chicago, Illinois 60611, United States
  • Riley Hospital for Children at Indiana University Health
    Indianapolis, Indiana 46202, United States
  • Johns Hopkins Hospital
    Baltimore, Maryland 21287, United States
  • Boston Children's Hospital
    Boston, Massachusetts 02115, United States
  • Children's Respiratory and Critical Care Specialists, P.A., Children's Hospitals and Clinics of Minnesota
    Minneapolis, Minnesota 55404, United States
  • The Children's Mercy Hospital
    Kansas City, Missouri 64108, United States
  • Cardinal Glennon Children's Hospital - St. Louis University
    Saint Louis, Missouri 63104, United States
  • University of Rochester Medical Center
    Rochester, New York 14642, United States
  • University of North Carolina Hospitals
    Chapel Hill, North Carolina 27514, United States
  • Wake Forest University School of Medicine - Brenner Children's Hospital
    Winston-Salem, North Carolina 27157, United States
  • Cincinnati Children's Hospital Medical Center
    Cincinnati, Ohio 45229, United States
  • Children's Hospital of Philadelphia
    Philadelphia, Pennsylvania 19104, United States
  • Children's Medical Center of Dallas
    Dallas, Texas 75235, United States
  • Cook Children's Medical Center
    Fort Worth, Texas 76104, United States
  • University of Utah / Primary Children's Medical Center
    Salt Lake City, Utah 84132, United States
  • Seattle Children's Hospital
    Seattle, Washington 98105, United States
  • University of Wisconsin Hospital and Clinics
    Madison, Wisconsin 53792, United States
  • McGill University Health Centre, Glen Site, Montreal Children's Hospital
    Montreal, Canada
  • The Hospital for Sick Children
    Toronto, Canada
  • British Columbia's Children's Hospital
    Vancouver, Canada
09

References and documents

Publications

  • Rayment JH, Asfour F, Rosenfeld M, Higgins M, Liu L, Mascia M, Paz-Diaz H, Tian S, Zahigian R, McColley SA. A Phase 3, Open-Label Study of Lumacaftor/Ivacaftor in Children 1 to Less Than 2 Years of Age with Cystic Fibrosis Homozygous for F508del-CFTR. Am J Respir Crit Care Med. 2022 Nov 15;206(10):1239-1247. doi: 10.1164/rccm.202204-0734OC. PubMed 35771568 ↗
  • Southern KW, Murphy J, Sinha IP, Nevitt SJ. Corrector therapies (with or without potentiators) for people with cystic fibrosis with class II CFTR gene variants (most commonly F508del). Cochrane Database Syst Rev. 2020 Dec 17;12(12):CD010966. doi: 10.1002/14651858.CD010966.pub3. PubMed 33331662 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No — Details on Vertex data sharing criteria and process for requesting access can be found at: https://www.vrtx.com/independent-research/clinical-trial-data-sharing

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2018 to primary completion in Oct 2021, 37 months.

Results were first posted in Jan 2023, 1 year 2 months after primary completion.

Of 58 industry-sponsored phase 3 interventional studies under Cystic Fibrosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 14 and three quarters within 36. This study's 37 months is above that.

Counting every sponsor, half of 67 studies reached it within 26 months; a quarter within 16 and three quarters within 39.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 18, 2018
First posted
Jul 26, 2018
StartActual
Sep 7, 2018
Primary completionActual
Oct 29, 2021
CompletionActual
Oct 29, 2021
Results first posted
Jan 6, 2023
Last update
Jan 6, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 6, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03601637
Responsible party
Sponsor
First posted
Jul 26, 2018
Start date
Sep 7, 2018
Primary completion
Oct 29, 2021
Completion
Oct 29, 2021
Results posted
Jan 6, 2023
Last update
Jan 6, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Dec 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Lumacaftor · Ivacaftor

Start the discussion